Alnylam Pharmaceuticals: Bet or Fold?

A slew of analysts raised their price targets for Alnylam Pharmaceuticals after the drug maker's stock spiked yesterday following the release of clinical trial data. But one analyst says its time to sell. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.